How RNA modifications affect blood vessel growth in lung cancer
Official title: 3' RNA modification enzymes regulate tumor angiogenesis in non-small lung cancer
Funded at Yale University · NIH-10791492 · Data updated 2026-11-12
This study is looking at how certain changes in RNA in blood vessel cells affect the growth of tumors in people with non-small cell lung cancer, and it hopes to find new ways to help improve treatment for patients.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Yale University NIH-funded |
| Lab location | 1 site (New Haven, United States) |
| Project start | July 10, 2024 |
| Project end | June 30, 2026 |
| Funding year | 2024 |
| Award (this year) | $430,684 |
| NIH project number | 1R21CA287273-01 |
| Project ID | NIH-10791492 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with non-small cell lung cancer, particularly those with KRAS mutations or p53 abnormalities.
✕Less likely to help
Patients with other types of lung cancer or those without the specific genetic mutations being studied may not benefit from this research.
What this research studies
This research investigates the role of specific RNA modifications in tumor endothelial cells (TECs) and their impact on blood vessel growth in non-small cell lung cancer (NSCLC). The study focuses on how vascular endothelial growth factor (VEGF) influences the levels of microRNAs, particularly miR-1, which is known to suppress tumor growth. By analyzing TECs from NSCLC patients, the researchers aim to understand the mechanisms behind miR-1 downregulation and its effects on tumor angiogenesis. The findings could lead to new therapeutic strategies targeting these molecular pathways to improve patient outcomes.
Why it matters
Potential benefit: If successful, this research could lead to novel treatments that inhibit tumor blood vessel growth, potentially reducing tumor size and improving survival rates for lung cancer patients.
How similar studies have gone: Previous studies have shown promising results in targeting microRNAs for cancer treatment, indicating that this approach has potential for success.
Where this research is happening
-
Yale University
New Haven, United States Active
Researchers
- Principal investigator: Takyar, Seyedtaghi — Yale University
- Study coordinator: Takyar, Seyedtaghi
Related research
Other NIH-funded projects on the same topics.
-
Blood-based markers to identify lung cancer risk in never-smokers
A researchers team at NYU School of Medicine is testing blood tests that might flag higher lung cancer risk in people who have never smoked, helping decide who might need screening.
-
Integrative Analysis of Lung Cancer Risk and Its Causes
A large, multi-part study at the University of New Mexico is exploring why lung cancer happens and how to better prevent and detect it.
-
Integrative Analysis of Lung Cancer Risk and Causes
A large NIH project is exploring how tobacco use, behavior, biology, and screening practices influence lung cancer risk and outcomes to help prevent and detect it earlier.
-
Digital health strategies to expand lung cancer screening in safety-net clinics
A funded project aims to help low-resource clinics increase the use of lung cancer screening for patients who smoke or are at risk.
-
Proteomics-guided matching of lung cancer tumors to preclinical models
This grant aims to improve how we match a patient’s lung cancer tumor to the right preclinical models using protein data.
-
Optimizing lung cancer care with smart tools for prevention, early detection, treatment, and survivorship
A U01 grant using AI and biomarkers to improve lung cancer prevention, screening, treatment, and survivorship care for people at risk or living with lung cancer.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.